The TECNIS PureSee™ IOL features a purely refractive design that delivers uninterrupted, high-quality, vision with high ...

Pfizer's robust R&D pipeline is expected to drive future growth and offset patent expirations. Read why I maintain my buy ...

Alvotech and Teva Pharmaceuticals announced the US Food and Drug Administration (FDA) has accepted for review a Biologics ...

New World Medical received 510 (k) clearance from the US Food and Drug Administration (FDA) for its VIA360 Surgical System ...

We can refer to full-year 2019 revenue of about $51 billion and the company's comments about potential revenue of more than ...

We spend plenty of time thinking about our workouts and what we eat, but how much attention do we give our eye health? The World Health Organization reports that around 2.2 billion people struggle ...

The company implemented cost-cutting measures and expects to save $4.5 billion by the end of this year, and another $1.5 billion by simplifying its manufacturing operations by 2027. On an adjusted ...

US pharmaceutical giant Pfizer Inc returned to profit in the fourth quarter from a loss in the same period of the previous year, the company reported on Tuesday, while confirming its outlook for ...

I’ve said this before: I’m no eye-cream evangelist. I’m a firm believer that your regular moisturizer should work just fine for the skin under your eyes as long as it isn’t too heavy and ...

the company earned 63 cents per share for the three months ended Dec. 31, compared with the average analyst estimate of 47 cents per share, according to data compiled by LSEG. Pfizer is facing ...

With just one asset in weight loss moving through the clinic, Pfizer targets the space for potential dealmaking, as well as bringing assets over from China. As Pfizer beat analyst expectations for ...

Seigerman said that Pfizer's consistent commercial progress drove the fourth-quarter beat, but investors will likely focus on the company's drug pipeline and returns from its 2023 acquisition of ...